文献速递生殖医学

配子捐赠中生殖遗传携带者筛查的利益相关者体验与观点:范围综述

Stakeholders' experiences and perspectives of reproductive genetic carrier screening in gamete donation: a scoping review.
PubMed 文献 · Hum Reprod · 2025-01-01

该范围综述检索四个数据库及引文,纳入29项研究,探讨配子捐赠中生殖遗传携带者筛查(RGCS)对利益相关者的影响。结果显示RGCS影响捐赠者自主权、接受者决策、医务人员信心及第三方服务提供者的供者池管理。

要点

  • RGCS给捐赠者自主权、知情同意和结果披露带来新挑战。
  • 接受者重视RGCS,但决策受费用、时间和遗传知识素养影响。
  • 医务人员支持RGCS但自觉技能和经验不足,第三方服务提供者面临供者可用性挑战。

核心结论

  • RGCS技术需求增长可能影响捐赠者捐赠意愿及配子可及性,需进一步研究以建立更稳健证据基础和更清晰指南。

研究设计与样本

  • 范围综述,检索Medline、Embase、CINAHL和Scopus四个数据库并进行引文检索,纳入英文原创研究、立场声明和会议摘要,日期不限。
  • 共识别470项研究,标题和摘要筛选排除427项,全文审查排除14项,最终纳入29项研究。

主要发现

  • 衍生四个主题:RGCS给捐赠者自主权、知情同意和结果披露带来新挑战;接受者重视RGCS但决策受费用、时间和遗传知识素养影响;医务人员支持捐赠者和接受者但自觉技能和经验不足;第三方服务提供者通过RGCS管理携带者检出增加带来的供者可用性挑战。
  • 大多数纳入研究在美国私人医疗体系内进行,该体系允许对配子捐赠者给予补偿。

临床怎么用

  • 作者认为,第三方服务提供者可完善排除标准,将携带者阳性的捐赠者纳入供者池,或增加接受者在捐赠者选择中的参与。
  • 作者认为,从事配子捐赠的医务人员需要更多关于RGCS的指导和培训。
  • 作者认为,需要进一步研究以建立更稳健的证据基础,并制定配子捐赠中RGCS的更清晰指南。

局限性

  • 本综述仅限于英文发表的文章。
  • 描述RGCS使用了多种术语,因此可能未识别所有相关文章。
  • 大多数纳入研究在美国私人医疗体系内进行,该体系允许对配子捐赠者给予补偿,这可能影响结果及对其他医疗体系不同国家的适用性。
  • 需要进一步研究以建立更稳健的证据基础并制定更清晰指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is known about stakeholders' experiences and perspectives with reproductive genetic carrier screening (RGCS) in gamete donation? SUMMARY ANSWER: RGCS has impacted donors' autonomy, recipients' decision-making, healthcare professionals' confidence, and third-party service providers' management of the donor pool. WHAT IS KNOWN ALREADY: Growing acceptance of diverse family structures and advances in RGCS technology have driven demand for RGCS in gamete donation, yet its clinical, social, and ethical implications remain poorly understood. STUDY DESIGN, SIZE, DURATION: A scoping review of four databases (Medline, Embase, CINAHL, and Scopus) with citation searching was conducted to identify original research, position statements, and conference abstracts published in English with an unrestricted date range. PARTICIPANTS/MATERIALS, SETTING, METHODS: Of the 470 studies identified, 427 were excluded during title and abstract screening and 14 during full-text review based on inclusion and exclusion criteria. For the 29 studies included, data were extracted in excel, and NVivo was used to code data and derive themes. MAIN RESULTS AND THE ROLE OF CHANCE: Four themes regarding stakeholders' experiences and perspectives with RGCS in gamete donation were derived: (i) RGCS presented new challenges regarding donor autonomy, informed consent, and result disclosure; (ii) recipients valued RGCS but decision-making was also shaped by cost, time constraints, and genetic literacy; (iii) healthcare professionals supported donors and recipients with RGCS, yet felt unskilled and inexperienced; and (iv) third-party service providers managed donor availability challenges from increased carrier detection through RGCS. LIMITATIONS, REASONS FOR CAUTION: This review was restricted to articles published in English. A range of terms were used to describe RGCS; thus, it is possible that not all relevant articles were identified in the search. Most included studies were conducted in the USA within a private medical system that permits compensation for gamete donors, which may shape the results and relevance to other countries with differing healthcare systems. WIDER IMPLICATIONS OF THE FINDINGS: Our findings suggest that the growing demand for RGCS technology may impact donors' willingness to donate and the availability of donor gametes. Third-party service providers may refine their exclusion criteria to include donors with a positive carrier status in the donor pool or increase the involvement of recipients in donor selection. Healthcare professionals working in gamete donation require more guidance and training on RGCS. Further research is required to establish a more robust evidence base regarding how RGCS impacts stakeholders and to establish clearer guidelines regarding RGCS in gamete donation. STUDY FUNDING/COMPETING INTEREST(S): This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. REGISTRATION NUMBER: n/a.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Porwal D, Newton G, Mansour J, et al. Stakeholders' experiences and perspectives of reproductive genetic carrier screening in gamete donation: a scoping review. Hum Reprod. 2025. PMID: 40611508. doi:10.1093/humrep/deaf128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。